Fingerprint
Dive into the research topics where Jared Henderson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma
Akkad, N., Feng, L., Westin, J. R., Hagemeister, F. B., Lee, H. J., Fayad, L., Ahmed, S., Nair, R., Rodriguez, M. A., Strati, P., Chihara, D., Flowers, C. R., Claret, L., Ibanez, K., Wang, M., Fowler, N., Henderson, J., Davis, R. E., Neelapu, S. S. & Green, M. & 1 others, , Sep 9 2025, In: Blood Advances. 9, 17, p. 4396-4404 9 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Link opens in a new tab Scopus citations -
A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma
Strati, P., Feng, L., Tyshevich, A., Shavronskaya, D., Alesse, J., English, N., Sheehan, E., Syzrantsev, N., Nesmelov, A., Zhuang, T. Z., Chihara, D., Westin, J. R., Ahmed, S., Fayad, L. E., Henderson, J., Dent, K., McChesney, E., Neelapu, S. S. & Flowers, C. R., Oct 1 2025, In: Clinical Cancer Research. 31, 19, p. 4079-4088 10 p.Research output: Contribution to journal › Article › peer-review
Open Access6 Link opens in a new tab Scopus citations -
Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement
Yang, H., Zhang, W., Ravanmehr, V., Cui, G., Bowman, K., Chen, R., Henderson, J. M., Lockman, S., Rojas, E., Wilson, A., Parsons, S., Mechaly, A., Regad, L., Haouz, A., Flowers, C. R., Neelapu, S., Nastoupil, L., Davis, R. E., Deng, Q. & Rodrigues-Lima, F. & 1 others, , Jul 10 2025, In: Blood. 146, 2, p. 191-205 15 p.Research output: Contribution to journal › Article › peer-review
Open Access6 Link opens in a new tab Scopus citations -
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial
Strati, P., Feng, L., Westin, J. R., Nair, R., Fayad, L. E., Rodriguez, M. A., Chihara, D., Malpica, L., Henderson, J., Gallardo, M., Rivera, M., Wang, I., Bolshakova, A., Radko, A., Kurtz, D., Alig, S. K., Flowers, C. R., Alizadeh, A. A. & Neelapu, S. S., Dec 2025, In: Nature communications. 16, 1, 7300.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Scopus citations -
Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy
Strati, P., Brandt, A., Lionel, A. C., Henderson, J., Westin, J. R., Adkins, S., Shpall, E. J., Kebriaei, P., Ramdial, J., Saini, N., Ahmed, S., Flowers, C., Neelapu, S. S. & Hildebrandt, M. A. T., Oct 9 2025, In: Journal for immunotherapy of cancer. 13, 10, e012401.Research output: Contribution to journal › Article › peer-review
Open Access